Literature DB >> 29614680

Novel GRN Mutations in Alzheimer's Disease and Frontotemporal Lobar Degeneration.

Irene Piaceri1, Daniele Imperiale2, Enrico Ghidoni3, Cristiana Atzori2, Silvia Bagnoli1, Camilla Ferrari4, Silvana Ungari5, Luca Ambrogio5, Sandro Sorbi1,4, Benedetta Nacmias1.   

Abstract

BACKGROUND: During the twentieth century, frontotemporal dementia (FTD) was often misdiagnosed, confused with Alzheimer's disease or psychiatric disorders, jeopardizing care and research.
OBJECTIVE: To analyze the FTD genes in the DNA samples of patients belonging to families clinically classified as probable Alzheimer's disease (FAD) in the early 1990s and not carrying mutation in the three main genes linked to FAD (Presenilin 1, Presenilin 2, and Amyloid precursor protein).
METHODS: The genetic screening was performed on 63 probands diagnosed as FAD before the early 2000s.
RESULTS: Four patients out of the 63 studied (4/63, 6.3%) resulted as carrying four different GRN genetic variations: p.T272SfsX10, p.R110X, p.C149LfsX10, and p.W304C. The first two mutations (p.T272SfsX10, p.R110X) are the most frequent ones in Italy in FTD patients; the latter two (p.C149LfsX10 and p.W304C) are not described in the scientific literature.
CONCLUSION: Our data suggest that it can be important to re-examine FAD patients diagnosed when the FTD spectrum was not well recognized and the causative FTD genes had not yet been identified. Moreover, we propose initially analyzing genes associated with the first form of suspected dementia and, if the results are negative, studying genes implicated in the other form of dementia.

Entities:  

Keywords:  Alzheimer’s disease; GRN; frontotemporal dementia; mutation

Mesh:

Substances:

Year:  2018        PMID: 29614680     DOI: 10.3233/JAD-170989

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  2 in total

1.  Progranulin mutations in clinical and neuropathological Alzheimer's disease.

Authors:  Badri N Vardarajan; Dolly Reyes-Dumeyer; Angel L Piriz; Rafael A Lantigua; Martin Medrano; Diones Rivera; Ivonne Z Jiménez-Velázquez; Eden Martin; Margaret A Pericak-Vance; William Bush; Lindsay Farrer; Jonathan L Haines; Li-San Wang; Yuk Yee Leung; Gerard Schellenberg; Walter Kukull; Philip De Jager; David A Bennett; Julie A Schneider; Richard Mayeux
Journal:  Alzheimers Dement       Date:  2022-02-09       Impact factor: 16.655

2.  Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome.

Authors:  Denis A Baird; Jimmy Z Liu; Jie Zheng; Solveig K Sieberts; Thanneer Perumal; Benjamin Elsworth; Tom G Richardson; Chia-Yen Chen; Minerva M Carrasquillo; Mariet Allen; Joseph S Reddy; Philip L De Jager; Nilufer Ertekin-Taner; Lara M Mangravite; Ben Logsdon; Karol Estrada; Philip C Haycock; Gibran Hemani; Heiko Runz; George Davey Smith; Tom R Gaunt
Journal:  PLoS Genet       Date:  2021-01-08       Impact factor: 5.917

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.